131 related articles for article (PubMed ID: 38452447)
1. Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study.
Firat O; Kara E; Malkan ÜY; Demirkan K; Inkaya AÇ
Thromb Res; 2024 Apr; 236():155-160. PubMed ID: 38452447
[TBL] [Abstract][Full Text] [Related]
2. Tigecycline-associated hypofibrinogenemia in a real-world setting.
Campany-Herrero D; Larrosa-Garcia M; Lalueza-Broto P; Rivera-Sánchez L; Espinosa-Pereiro J; Mestre-Torres J; Pigrau-Serrallach C
Int J Clin Pharm; 2020 Aug; 42(4):1184-1189. PubMed ID: 32504166
[TBL] [Abstract][Full Text] [Related]
3. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.
Lei H; Liu X; Li Z; Wang C
J Chemother; 2023 Jul; 35(4):292-297. PubMed ID: 35904191
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for tigecycline-induced hypofibrinogenaemia.
Zhang Q; Wang J; Liu H; Ma W; Zhou S; Zhou J
J Clin Pharm Ther; 2020 Dec; 45(6):1434-1441. PubMed ID: 32860258
[TBL] [Abstract][Full Text] [Related]
7. Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: A case report.
Li ZK; Zheng P
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):466-470. PubMed ID: 37548456
[TBL] [Abstract][Full Text] [Related]
8. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.
Wu X; Zhao P; Dong L; Zhang X
Medicine (Baltimore); 2017 Dec; 96(49):e9124. PubMed ID: 29245350
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
10. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
11. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
12. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.
Yang X; Jin L; Luo X; Wang M; Zhu H; Zhou Y; Ge W
Int J Infect Dis; 2022 Oct; 123():136-142. PubMed ID: 36028209
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
14. Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage.
Koller T; Parera Ruiz A; Diaz-Ricart M; Gómez Caro AM
Drugs Today (Barc); 2021 Mar; 57(3):219-239. PubMed ID: 33729219
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hypofibrinogenemia in blunt trauma patients on admission.
Kimura Y; Kimura S; Sumita S; Yamakage M
J Anesth; 2015 Apr; 29(2):242-8. PubMed ID: 25112812
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study.
Xie W; Ma K; Xu Z; Xie J; Lu X; Wang X
Transl Androl Urol; 2022 Oct; 11(10):1410-1418. PubMed ID: 36386261
[TBL] [Abstract][Full Text] [Related]
17. Rare severe hypofibrinogenemia induced by tissue plasminogen activator in stroke patients: Case report.
Huang X; Cao L
Medicine (Baltimore); 2021 Mar; 100(9):e24978. PubMed ID: 33655967
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients.
Abrahamyan L; Tomlinson G; Callum J; Carcone S; Grewal D; Bartoszko J; Krahn M; Karkouti K
JAMA Surg; 2023 Mar; 158(3):245-253. PubMed ID: 36598773
[TBL] [Abstract][Full Text] [Related]
19. Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations.
Wypasek E; Klukowska A; Zdziarska J; Zawilska K; Treliński J; Iwaniec T; Mital A; Pietrys D; Sydor W; Neerman-Arbez M; Undas A
Thromb Res; 2019 Oct; 182():133-140. PubMed ID: 31479941
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.
Huang YT; Yu CI; Chen PY; Wang CC; Wu CC
Infect Drug Resist; 2021; 14():4949-4955. PubMed ID: 34858035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
